| Indication | metastatic or locally advanced cutaneous squamous cell carcinoma |
| Drug | cemiplimab |
| Mechanism of Action | PD-1 inhibitor |
| Company | Regeneron Pharmaceuticals, Inc. |
| Category | Regulatory Milestone |
| Sub Category | Label Update / Expansion |
| Therapeutic Area | Oncology |
| Regulatory Body | European Commission |
| Approved Region | European Union |
| Approval Date | November 17, 2026 |
| Extended Dosing Regimen | 700 mg every six weeks |
| Initial Dosing Regimen | 350 mg every three weeks for 12 weeks |
| Reduced Infusion Time | 15-30 minutes |
| Number of Approved Indications (EU) | Six |
| US Regulatory Status | Supplemental Biologics License Application (sBLA) under review |
| US Decision Expected | March 2027 |
| US Regulatory Agency | FDA |
EU Approves Extended Dosing and Faster Infusion for Regeneron's Libtayo
Regeneron Pharmaceuticals announced that the European Commission (EC) has approved an alternative, flexible dosing schedule for Libtayo (cemiplimab) across all its six approved indications for skin, lung, and cervical cancers. This approval introduces an extended dosing regimen of 700 mg every six weeks, following an initial 12 weeks of 350 mg every three weeks. Additionally, it allows for reducing subsequent infusion times of the 350 mg dose from 30 minutes to 15-30 minutes, provided the first infusion was well-tolerated. This aims to enhance the patient treatment experience by reducing the frequency of clinic visits and shortening infusion durations, offering greater flexibility for both patients and healthcare providers. The decision is supported by clinical safety and efficacy data, integrated with pharmacokinetic and pharmacodynamic modeling.
- The European Commission has approved a new, less frequent dosing schedule for Libtayo, allowing patients to receive a higher dose of 700 mg every six weeks. This extended interval applies after an initial 12-week treatment period of 350 mg every three weeks. This significant change is designed to alleviate the burden of frequent hospital visits for patients managing advanced cancers, improving convenience and adherence to long-term treatment.
- In addition to the extended dosing, the approval also includes an option to reduce the infusion time for the 350 mg dose. After a patient's first 30-minute infusion is well-tolerated, subsequent infusions can be completed in a shorter window of 15 to 30 minutes. This reduction in infusion duration further enhances patient comfort and clinic efficiency, freeing up valuable time for both patients and healthcare facilities.
- The flexible dosing and faster infusion times are applicable across all six of Libtayo's existing approved indications in the European Union, encompassing various forms of skin, lung, and cervical cancers. This broad applicability is underpinned by robust clinical safety and efficacy data from Libtayo's extensive development program, complemented by comprehensive pharmacokinetic and pharmacodynamic modeling and simulation data, ensuring the changes maintain therapeutic effectiveness.
Libtayo's Established Safety Profile Supports EU Dosing Flexibility
In metastatic basal cell carcinoma after hedgehog pathway inhibitors, 54 patients receiving cemiplimab 350 mg intravenously every 3 weeks reported fatigue in 23 [43%] and diarrhoea in 20 [37%] as the most common treatment-emergent adverse events, with no treatment-related deaths. In locally advanced basal cell carcinoma after hedgehog inhibitor therapy, among 84 patients receiving the same regimen, Grade 3-4 treatment-emergent adverse events occurred in 40 (48%), most commonly hypertension in four [5%] and colitis in four [5%], serious treatment-emergent adverse events occurred in 29 (35%), and there were no treatment-related deaths.
In cutaneous squamous cell carcinoma, safety varied by setting and population. In the neoadjuvant phase 2 study in resectable stage II-IV (M0) disease, among 16 patients who received adjuvant cemiplimab, four (25%) had grade 3 adverse events, including one (6%) with increased blood potassium, one (6%) with traumatic limb amputation, and two with serious adverse events (one [6%] cardiomyopathy and one [6%] hypophysitis), with no grade 4 adverse events or treatment-related deaths. Across Phase I/II trials, fatigue, diarrhea, pruritus, and rash were fairly common, only 9.8% of adverse events required cessation of therapy, severe events were primarily immune-mediated including pneumonitis, myocarditis, myositis, and autoimmune hepatitis, and the risk of treatment-related death was 3% in clinical trials. In real-world cohorts, 17 (77%) of 22 patients experienced 24 adverse events comprising 45% serious adverse events grade ≥3 and one serious adverse event grade 5 (myositis), with nine patients (41%) definitively discontinuing due to adverse events; in 106 first-line patients, the proportion with immune-related adverse events ≥grade 3, cemiplimab discontinuation, and hospitalization for immune toxicity was 27.4%, 31.1%, and 11.3%, respectively, with increased odds of discontinuation in patients aged 75-84 years (p = 0.05) and increased hospitalizations in patients ≥85 years (OR = 5.00, 95% CI = 0.97-37.52) with two treatment-related deaths; in REACT-CEMI (n=105), 87% experienced no treatment interruptions, 13% (n=14/105) interrupted due to immune-related adverse reactions (47% [n=9/19] of interruption events), and 19% (n=20/105) experienced immune-related adverse reactions. Rare events included Vogt-Koyanagi-Harada-like syndrome with panuveitis, subretinal fibrosis, and exudative retinal detachment requiring discontinuation and high-dose intravenous and topical steroids, and severe hypersensitivity with anaphylaxis to both pembrolizumab and cemiplimab.
In combination and special populations, fianlimab plus cemiplimab showed any-grade treatment-emergent adverse events in 90% with monotherapy, 87% with combination, and 87% transitioning from monotherapy to combination, with one dose-limiting toxicity of increased blood creatine phosphokinase and myasthenic syndrome at 3 mg/kg fianlimab plus cemiplimab and no maximum tolerated dose reached; in expansion cohorts the most common treatment-related events were fatigue (15%), rash (12%), pruritus (10%), infusion-related reaction (10%), and adrenal insufficiency (10%). In adults with suppressed human immunodeficiency virus on antiretroviral therapy, one participant had probable thyroiditis grade 2 and another had possible hepatitis grade 3 after a single low-dose (0.3 mg/kg) infusion, with no other cemiplimab-related serious adverse events, immune-related adverse events, or grade 3 or higher adverse events. In a community-based immune checkpoint inhibitor colitis series including cemiplimab, outcomes were resolution with steroids (64.8%), antibiotics (5.4%), biologic (10.8%), surgery (5.4%), and hospice (8.1%). In recurrent or metastatic cervical cancer, Cox proportional hazard modeling showed no trend between cemiplimab exposure and immune-related adverse events.
Cemiplimab's Proven Efficacy in Advanced Cutaneous Squamous Cell Carcinoma
Cemiplimab, a human monoclonal antibody directed against programmed cell death-1 receptor that acts by blocking T-cell inactivation, is the first drug approved for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation, and anti-PD-1 agents are the first-line systemic treatment for patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation, with cemiplimab being the first approved systemic agent for advanced cSCC by the Food and Drug Administration/European Medicines Agency. In the pooled longer term data from three groups of a phase 2 study (n=193), patients received cemiplimab 3 mg/kg every 2 weeks (group 1, metastatic CSCC [mCSCC], n=59; group 2, locally advanced CSCC, n=78) or cemiplimab 350 mg every 3 weeks (group 3, mCSCC, n=56), with median duration of follow-up of 15.7 months. Overall, objective response rate (ORR) per independent central review (ICR) was 46.1% (95% CI: 38.9% to 53.4%), with complete response (CR) rates of 20.3%, 12.8%, and 16.1% for groups 1, 2, and 3, respectively, and in the primary analysis of fixed dosing, ORR per ICR was 41.1% (95% CI, 28.1% to 55.0%) in Group 3, 49.2% (95% CI, 35.9% to 62.5%) in Group 1, and 45.2% (95% CI, 35.9% to 54.8%) in both groups combined.
Real-world evidence supports efficacy in locally advanced (LA) and metastatic disease, including in elderly, frail, and immunosuppressed patients. Among 31 patients with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) not amenable to surgery or radiotherapy treated between November 2018 and March 2023, 20 (64.5%) achieved a complete response, 6 (19.4%) achieved a partial response, and 2 (6.5%) experienced disease progression, yielding an ORR of 83.9%, which exceeded the 46.1% reported in the EMPOWER-CSCC 1 trial. In 83 patients with lacSCC (n = 53) and mcSCC (n = 30), the objective response rate (ORR) was 49.4%, with a complete response (CR) in 15.7% and a partial response (PR) in 33.7%, while in 40 patients with refractory LA and metastatic cSCC, 16 (40%) had LA disease and 24 (60%) had metastatic disease with median treatment duration of 3.5 months (range: 0.6-29.4 months), and in 30 non-selected patients with laCSCC (25) and mCSCC (five) with median age of 81 years (range, 36-95) and frailty prevalence of 83%, 23 responses (76.7%) with nine complete responses (30%) were reported, including an overall response in four of five immunosuppressed patients.
Survival outcomes demonstrate durable benefit with sustained response and prolonged overall survival (OS). Among patients with partial response or CR in the pooled phase 2 dataset, the estimated proportion of patients with ongoing response at 12 months from the first objective response was 87.8% (95% CI: 78.5% to 93.3%), with median DOR not reached and median time to CR of 11.2 months, and Kaplan-Meier estimated probability of overall survival (OS) was 73.3% (95% CI: 66.1% to 79.2%) at 24 months, with median OS not reached. The 2-year OS of 73.5% in the 31-patient tertiary center cohort was comparable to the 73.3% reported in EMPOWER-CSCC 1, while in the 40-patient Canadian cohort median OS was not reached [NR; 95% confidence interval (CI) 9.1 months-NR] and median PFS was 11.5 months (95% CI 7.0 months-NR), and in the 83-patient cohort median progression-free survival (PFS) was 14 months (95% CI 9-55) and median overall survival (OS) 19 months (95% CI 10-39). Global Health Status (GHS)/QoL improvements were observed as early as cycle 2 and were significantly improved and durable until last assessment, with Kaplan-Meier estimate of median time to first clinically meaningful improvement for pain of 2.1 (95% CI: 2.0 to 3.7) months, significantly improved in responders versus non-responders (p<0.0001).
How Libtayo's New Dosing Addresses Cancer Treatment Challenges
Advanced cutaneous squamous cell carcinoma (cSCC) represents a minority of cases (<5%) but is often difficult to treat and characterised by a poor prognosis. Curative surgery or radiation is not feasible for all patients with locally advanced or metastatic disease, and systemic options carry efficacy, toxicity and patient-selection constraints.
No agreed definition of locally advanced disease: locally advanced CSCC was described as non-metastatic CSCC that is unlikely to be cured with surgery, radiotherapy or combination treatment, complicating identification of appropriate candidates for systemic therapy.
Limited options for inoperable or non-surgical candidates: radiotherapy should be considered as curative treatment for inoperable cSCC, or for non-surgical candidates, yet older patients may not be candidates for surgery due to frailty and/or increased risk of complications, and locally advanced cSCC tends to recur locally and/or can metastasize, especially in patients with high-risk features such as poorly differentiated histology and perineural invasion.
No definitive systemic standard from randomized comparison: in the absence of prospective randomized phase 3 trials to evaluate and compare the efficacy and safety of chemotherapeutics, epidermal growth factor receptor (EGFR) inhibitors and anti-PD-1 antibodies, no final recommendation for systemic therapy can be given for patients with locally advanced or metastatic cSCC.
Incomplete and toxic responses to checkpoint blockade: some patients experience inadequate responses or severe immune-related adverse events (AEs), indicating the need for improved therapies, and patients not eligible for anti-PD-1 treatment, e.g. in organ transplant recipients, or in patients refractory to anti-PD-1 may be offered EGFR inhibitors and/or chemotherapies.
Lack of predictive biomarkers: despite the biologic rationale for biomarker-guided treatment, tumor mutational burden and PD-L1 expression have not shown sufficiently consistent predictable values for clinical selection.
Unproven adjuvant benefit in high-risk disease: current evidence has not shown significant benefit for adjuvant radiotherapy for those with at least one high-risk factor with clear surgical margins, and KEYNOTE-630, which evaluated adjuvant pembrolizumab, was stopped for futility after an independent data monitoring committee review determined it was not meeting its prespecified recurrence-free survival threshold.
Frequently Asked Questions
References
- [1] Strum S, Climans S et al.. Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma. Journal of cutaneous medicine and surgery. 2024 Sep-Oct. 39056376
- [2] Stratigos AJ, Sekulic A et al.. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. The Lancet. Oncology. 2021 Jun. 34000246
- [3] Gross ND, Miller DM et al.. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. The Lancet. Oncology. 2023 Nov. 37875144
- [4] Challapalli A, Stewart G et al.. Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab). Frontiers in immunology. 2024. 39072317
- [5] Rashid Y, Devi S K et al.. Checkpoint Inhibitors and Beyond: A Systematic Review of Immunotherapy in Cutaneous Malignancies. Cureus. 2025 Dec. 41527622
- [6] Stevenson ML, Wang CQ et al.. Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab. JAMA dermatology. 2017 Apr 1. 28259107
- [7] Miodovnik M, Dolev Y et al.. Squamous cell carcinoma arising in chronically damaged skin (Marjolin's Ulcer): still an unmet need in the era of immunotherapy. The oncologist. 2025 Aug 4. 39656718
- [8] Gay CL, Bosch RJ et al.. Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy. Open forum infectious diseases. 2024 Mar. 38449916
- [9] Rischin D, Migden MR et al.. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. Journal for immunotherapy of cancer. 2020 Jun. 32554615
- [10] Strippoli S, Fanizzi A et al.. Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy. Frontiers in oncology. 2021. 34820323
- [11] Rischin D, Khushalani NI et al.. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. Journal for immunotherapy of cancer. 2021 Aug. 34413166
- [12] Argenziano G, Fargnoli MC et al.. Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion. Therapeutic advances in medical oncology. 2022. 35035534
- [13] Ye J, Ma Y et al.. Long-Term Clinical Benefit in EGFR-Mutant Lung Adenocarcinoma With Local Squamous Cell Carcinoma Transformation After EGFR TKI Resistance: A Case Report. Frontiers in oncology. 2022. 35692748
- [14] Lakhani NJ, Papadopoulos KP et al.. First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Dec 16. 39422598
- [15] Okano Y, Kunishige M et al.. Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient. Thoracic cancer. 2022 Feb. 34931476
- [16] Nguyen NP, Thariat J et al.. Immunotherapy and Hypofractionated Radiotherapy in Older Patients with Locally Advanced Cutaneous Squamous-Cell Carcinoma of the Head and Neck: A Proposed Paradigm by the International Geriatric Radiotherapy Group. Cancers. 2023 Oct 13. 37894347
- [17] Fu J, Yan YD et al.. A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer. Frontiers in pharmacology. 2024. 39834801
- [18] Lee A, Duggan S et al.. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma. Drugs. 2020 Jun. 32306208
- [19] Stratigos AJ, Garbe C et al.. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. European journal of cancer (Oxford, England : 1990). 2020 Mar. 32113942
- [20] Villani A, Ocampo-Garza SS et al.. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert opinion on drug safety. 2022 Jan. 34644510
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com














